Companies › CEBIOTEX
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout May 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 7-Ethyl-10-Hydroxycamptothecin (CEB-01) DNA topoisomerase I inhibitor | TOP1 | Phase 2 | Locally Resectable Pediatrics Tumors | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06986811 | 7-Ethyl-10-Hydroxycamptothecin (CEB-01) | Phase 2 | Locally Resectable Pediatrics Tumors | Oncology | May 2029 |
Targeted Therapy Technologies CNS Pharmaceuticals NanoEcho Syncromune Galecto Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.